Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG One-Pager on FDA’s Proposed Regulatory Framework for LDTs
-
Group Sign-on Letter to Congress Urging Modernization of the Clinical Laboratory Improvement Amendments (CLIA)
-
ACMG Comments to FDA Concerning the FDA Draft Guidance on the Framework for Regulatory Oversight of LDTs
-
ACMG Comments to FDA Concerning the FDA Draft Guidance on Notification and Medical Device Reporting for LDTs
-
Group Sign-on Letter to FDA Requesting Withdrawal of Draft Guidance for LDTs
-
Joint Comments to CMS Concerning MolDx Program, Medicare Coverage, and Impact on MoPath Gapfill Determinations
-
ACMG Letter to Palmetto GBA Requesting Reconsideration of Cytogenetic Microarray Coverage
-
ACMG Comments to NIH about Development of the Genetic Test Registry